A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients
- Registration Number
- NCT01513850
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Brief Summary
The purpose of this study is to Evaluate the efficacy and safety of Hepabulin IV (HBIG, a study drug) after liver transplantation.
- Detailed Description
A 52-week, Multi-center, Open label, Single arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg positive Liver Transplantation recipients
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 87
Inclusion Criteria
- HBsAg Positive candidate for HBV-related liver transplant
- Primary, single organ recipients
- written informed consent
Exclusion Criteria
- acute renal failure, Serum creatinin >1.5*ULN
- severe cardiac disease or other significant disease
- HAV, HCV or HIV positive
- Immunoglobulin A deficiency.
- History of hypersensitivity to Human Immunoglobulin.
- History of cancer within 5 years. (without HCC)
- History of alcohol or/and drug abuse.
- History organ transplantation.
- Within 30 days, participation in another clinical trial and use of an investigational product.
- Subject suffer from any acute or chronic medical, surgical or psychiatric condition or laboratory abnormality that, may increase the risk associated with the study participation or investigational product administration, or may interfere with the interpretation of study result.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Hepabulin IV Hepabulin IV -
- Primary Outcome Measures
Name Time Method HBV(HBsAg) recurrence 52 weeks
- Secondary Outcome Measures
Name Time Method viral Marker of HBV 52 weeks Time to recurrence 52 weeks Survival 52 weeks
Trial Locations
- Locations (1)
SKChemicals
🇰🇷Seongnam, Gyunggi-do, Korea, Republic of